Zynex (ZYXI) Risk Assessment

View and export this data going back to 2019. Start your Free Trial

What is Zynex Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Zynex is: Low Risk: Strong fundamentals, worth long-term holding.

Competitive Comparison of Zynex's Risk Assessment

For the Medical Distribution subindustry, Zynex's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zynex's Risk Assessment Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Zynex's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Zynex's Risk Assessment falls into.

Zynex (NAS:ZYXI) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Zynex Risk Assessment Related Terms

Thank you for viewing the detailed overview of Zynex's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Zynex (ZYXI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Zynex Inc (NAS:ZYXI) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

9555 Maroon Circle, Englewood, CO, USA, 80112

Website

https://www.zynex.com

Zynex Inc is engaged in the manufacturing and marketing of medical devices. It operates through one primary business segment, Electrotherapy and Pain Management Products. The business activities of the company are carried out through its subsidiaries. The company designs, manufacture, and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. it also develops and markets medical devices for non-invasive cardiac monitoring, the products of which are under development. The company markets Zynex-manufactured products which include NexWave, NeuroMove, InWave E-Wave and others.

Executives

Daniel J Moorhead	officer: Chief Financial Officer	9777 PYRAMID CT, STE 100, ENGLEWOOD CO 80112
Anna Lucsok	officer: See Remarks	9555 MAROON CIRCLE, ENGLEWOOD CO 80112
Thomas Sandgaard	director, 10 percent owner, officer: President, CEO and Chairman	10506 KALAHARI CT., LONE TREE CO 80124
Neil Friery	officer: See Remarks	C/O ZYNEX, INC. 9555 MAROON CIRCLE, ENGLEWOOD CO 80112
Joshua R. Disbrow	director	AMPIO PHARMACEUTICALS, INC., 5445 DTC PARKWAY, SUITE 925, GREENWOOD VILLAGE CO 80111
Barry D Michaels	director	6275 NANCY RIDGE DRIVE, SUITE 110, SAN DIEGO CA 92121
Michael D Cress	director	3409 ESPERANZA CROSSING SUITE 7110, AUSTIN TX 78758
Sandgaard Holdings Llc	10 percent owner	9555 MAROON CIRCLE, ENGLEWOOD CO 80112
Giuseppe Papandrea	officer: Chief Operating Officer	C/O ZYNEX, INC. 9555 MAROON CIRCLE, ENGLEWOOD CO 80112